Cleopatra Hospitals Group Roadshow Presentation
Disclaimer This presentation is being provided to you on a confidential basis and may not be distributed or reproduced in any form. This presentation is intended for information purposes only and does not constitute or form part of an offer for sale or subscription or an invitation or solicitation of an offer to subscribe for or purchase securities of any kind and neither this document nor anything contained herein shall form the basis of any contract or commitment from any party whatsoever This presentation has been prepared by Cleopatra Hospitals Group (“CHG”) and reflects the management’s current expectations or strategy concerning future events and are subject to known and unknown risks and uncertainties. Some of the statements in this presentation constitute "forward-looking statements" that do not directly or exclusively relate to historical facts. These forward-looking statements reflect CHG’s current intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors, many of which are outside CHG ’s control. Important factors that could cause actual results to differ materially from the expectations expressed or implied in the forward-looking statements include known and unknown risks. CHG undertakes no obligation to revise any such forward-looking statements to reflect any changes to its expectations or any change in circumstances, events, strategy or plans. Because actual results could differ materially from CHG ’s current intentions, plans, expectations, assumptions and beliefs about the future, you are urged to view all forward-looking statements contained in this presentation with due care and caution and seek independent advice when evaluating investment decisions concerning CHG. No representation or warranty, express or implied, is made or given by or on behalf of CHG or any of its respective members, directors, officers or employees or any other person as to the accuracy, completeness or fairness of the information or opinions contained in or discussed at this presentation. These materials are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. By attending the presentation to which this document relates or by accepting this document you will be taken to have represented and warranted that you have read and agree to comply with the contents of this disclaimer. 2 Cleopatra Hospitals Group | Roadshow Presentation Excellence in Healthcare
Rights Issue - Overview Offer Type Rights Issue Trading of Rights Rights will be tradable on the EGX Offer Size EGP 700mn , divided into 1.4bn shares Outstanding No. of Shares 200,000,000 Post Capital Increase Number of Shares 1,600,000,000 Pre/Post Capital Increase Paid-in Capital 100,000,000 / 800,000,000 Offer Price EGP 0.5 (Par), excluding issuance fees Subscription Ratio 7.0x (Each shareholder as of the record date is entitled to subscribe to 7 new shares) Early Nov – Early Dec 2017 (1) Subscription Period Trading of Rights Exercise Period Early Nov – End of Nov 2017 (1) ≡ The proceeds will be mainly directed towards financing new hospital acquisitions – EGP 580mn Use of Proceeds ≡ Proceeds are also intended to partially repay the Group’s outstanding debt – EGP 120mn ≡ Lead Manager & Sole Bookrunner : EFG Hermes Investment Banking ≡ Legal Counsel: Matouk Bassiouny Syndicate ≡ Subscription Bank: Arab African International Bank Note(1): Expected dates; Subject to change based on regulatory approvals 3 Cleopatra Hospitals Group | Roadshow Presentation Excellence in Healthcare
Rights Issue - Key Dates October Dates Event SUN MON TUE WED THU FRI SAT 1 2 3 4 5 6 7 • EGM Approved Rights’ Issue 30 Sep 2017 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 • Investor Roadshow November 8 Oct – 12 Oct 2017 SUN MON TUE WED THU FRI SAT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 • Publish Public Subscription Notice (1) End of Oct 2017 19 20 21 22 23 24 25 26 27 28 29 30 December SUN MON TUE WED THU FRI SAT • Round 1 Subscription Period (1) Early Nov – Early Dec 2017 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 • Round 2 Subscription Period (1) Mid Dec 2017 31 Complete In Progress Note(1): Expected dates; Subject to change based on regulatory approvals 4 Cleopatra Hospitals Group | Roadshow Presentation Excellence in Healthcare
Today’s Presenters Dr. Ahmed Ezzeldin Khaled Hassan Hoda Yehia Chief Executive Officer Chief Financial Officer Investor Relations Director 5 Cleopatra Hospitals Group | Roadshow Presentation Excellence in Healthcare
Introduction to Cleopatra Hospitals Group 6 Cleopatra Hospitals Group | Roadshow Presentation Excellence in Healthcare
Cleopatra Hospitals Group 4 +20 Operational hospitals Years of subsidiary track at a Glance across our platform record 635 +2,000 Patient beds including Total medical staff including • Cleopatra Hospitals Group (the “ Group ” or “ CHG ”), is the largest private hospital 400 rooms c. 650 resident doctors and group in Egypt and consists of four operational hospitals all in Cairo, namely: /wards and 120 ICU beds c. 1400 nursing staff • Cleopatra Hospital (“CHC” or “Cleopatra”) 1,000 • Cairo Specialized Hospital (“CSH”) ( 53.2% ownership ) • Nile Badrawy Hospital (“NBH” or “Nile Badrawy”) ( 99.9% ownership ) c.1,000,000 Consultants mostly • Al Shorouk Hospital (“ASH” or “Al Shorouk”) ( 99.9% ownership ) University Professors and • Cases served LTM The Company went public on the Egyptian Stock Exchange (EGX) in June 2016 , and international renowned currently has a market cap of EGP 5,420mn (1) (USD 307 mn) (1) physicians • The platform was formed by The Abraaj Group , a leading private equity investor EGP 524 mn operating in global growth markets, in partnership with leading developmental and EGP 108 mn financial institutions • Consolidated revenues in The Company’s revenue went from EGP 413.4mn in 1H16 to EGP 523.9mn in 1H17, EBITDA in 1H17 with a 21% 1H17 with 27% growth and net profits increased from EGP 30.8mn in H116 to EGP 52.6mn in 1H17 margin vs. 1H16 Shareholder Structure and Share Performance Cleopatra Hospitals Group Stock Performance Share Information (2) Shareholder Structure Listing Venue Volume CLHO (Rebased to 100) EGX30 (Rebased to 100) Free Float, 20% Listing Date June 2016 350 201% Ticker Symbol CLHO EY 250 Market Capitalization EGP 5,420| USD 307 84% Initial Share Price EGP 9.0 150 Care Healthcare, Share Performance 50 201% | 60% 80% (Since Trading | YTD) Jun-16 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Oct-17 Index Inclusion EGX 70 | EGX 100 Source : Bloomberg Note (1): As of 3 Oct 2017 @ USD / EGP 17.64 Note (2): As of 3 Oct 2017 7 Cleopatra Hospitals Group | Roadshow Presentation Excellence in Healthcare
Presence in Attractive Catchment Areas Across Greater Cairo Location Mohandsein, Giza Location Heliopolis, Cairo Built-up Area 5,270 sqm Built-up Area 7,380 sqm Date Established 1996 Date Established 1984 # of Beds 121 # of Beds 167 West Cairo Acquisition (1) Location Dokki, Giza Built-up Area 6,500 sqm Date Established 1946 # of Beds 92 (2) Status Documents signed, pending closing Location Maadi, Cairo Location Heliopolis, Cairo Built-up Area 10,980 sqm Built-up Area 14,600 sqm Date Established 1985 Date Established 1976 # of Beds 143 # of Beds 204 Note (1): This acquisition is still pending the completion of certain condition precedents and may not be completed for the above mentioned or any other reason Note (2): expected to increase to 108 beds post expansion 8 Cleopatra Hospitals Group | Roadshow Presentation Excellence in Healthcare
Recommend
More recommend
